Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

The original Gene line-up have reunited and announced their first live show in over 20 years. Read NME‘s interview with frontman Martin Rossiter below, where he discusses what to expect from the ...

Patient was a 16-year-old teen, who underwent treatment in Dec First death reported after Elevidys treatment Liver injury a known risk with gene therapies March 18 (Reuters) - Sarepta Therapeutics ...

According to Monday’s news release, the candidate, OPK-88006, is set to be the first oral GLP-1/glucagon agonist to start human studies. Under the terms of the agreement, OPKO and Entera will split ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said Kevin McCulloch, President and COO of Xeris. "American Regent is the ...

Inherited repeat mutations in the HTT gene expand in neurons over decades before crossing a toxic threshold, revealing a long time window for therapy. CAG repeats in HTT are unstable, meaning that ...

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from Hologen.